Cancer clinical trials in the region Normandie

244 currently recruiting clinical trials
Region Normandie

Phase 3 Breast cancer #NCT07062965
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
Excluded previous treatments at localized stage
Chemotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Antibody Drug Conjugates (ADC)
3 recruiting sites
Pfizer
Phase 3 Colon cancer Rectal cancer #NCT06997497 #2024-517232-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06510374
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
10 recruiting sites
Ferring Pharmaceuticals
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05198960
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera Essential thrombocythemia Primary myelofibrosis
Required genetic anomalies
JAK2
19 recruiting sites
Hôpital Universitaire de Brest
Phase 3 Breast cancer #NCT06841354
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06476184 #2023-508260-30-01
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Other epithelial ovarian cancer
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
35 recruiting sites
ARCAGY/ GINECO GROUP
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05078047
Required histologic types
Cervical cancer
Required disease stage
Locally Advanced Metastatic
25 recruiting sites
UNICANCER
Phase 3 Head and neck cancer #NCT04892173
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Head and neck cancer #NCT07264075 #2025-522996-27-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
4 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)
Phase 3 Head and neck cancer #NCT06525220 #2023-510323-30-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
14 recruiting sites
Merus